Johan Christenson - Abionyx Pharma Director - Representative of HealthCap IV Bis
| ABNX Stock | EUR 1.22 0.03 2.40% |
Insider
Johan Christenson is Director - Representative of HealthCap IV Bis of Abionyx Pharma SA
| Age | 61 |
| Phone | 33 5 62 24 97 06 |
| Web | https://abionyx.com |
Abionyx Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2869) % which means that it has lost $0.2869 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.917) %, meaning that it generated substantial loss on money invested by shareholders. Abionyx Pharma's management efficiency ratios could be used to measure how well Abionyx Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Linda MSc | OSE Pharma SA | 56 | |
| Pr Roska | Gensight Biologics SA | N/A | |
| Benoit Canolle | Biophytis SA | 45 | |
| Scott Jeffers | Gensight Biologics SA | N/A | |
| Alain MD | OSE Pharma SA | N/A | |
| Prof Ehrlich | Abivax SA | N/A | |
| Regina Jehle | Abivax SA | N/A | |
| Silvia MD | OSE Pharma SA | N/A | |
| Clothilde Caillet | Gensight Biologics SA | N/A | |
| Raquel Lizarraga | Abivax SA | N/A | |
| FFPM MBA | Biophytis SA | 52 | |
| JoseAlain MD | Gensight Biologics SA | N/A | |
| Anne Pascard | Abivax SA | N/A | |
| Paul Gineste | Abivax SA | N/A | |
| Teylan | Biophytis SA | N/A | |
| Pierre MBA | Abivax SA | N/A | |
| JeanPascal PharmD | OSE Pharma SA | N/A | |
| Dominique MD | OSE Pharma SA | 68 | |
| Prof Cepko | Gensight Biologics SA | N/A | |
| Philippe Rousseau | Biophytis SA | 52 | |
| Brangre Vasseur | OSE Pharma SA | N/A | |
Management Performance
| Return On Equity | -0.92 | |||
| Return On Asset | -0.29 |
Abionyx Pharma SA Leadership Team
Elected by the shareholders, the Abionyx Pharma's board of directors comprises two types of representatives: Abionyx Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abionyx. The board's role is to monitor Abionyx Pharma's management team and ensure that shareholders' interests are well served. Abionyx Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abionyx Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gavin Sy, Director of Production | ||
| Emmanuel Huynh, Chairman of the Board | ||
| Ronald Barbaras, Director of Exploratory Biology | ||
| Constance Keyserling, Director of Clinical Development and Operations | ||
| Denis Lucquin, Director - Representative of Sofinnova | ||
| Renee Benghozi, Director of Clinical Research | ||
| Marc Riviere, Director | ||
| Cyrille Tupin, Chief Executive Officer, Executive Director | ||
| Nathalie Sabina, Executive Assistant | ||
| Johan Christenson, Director - Representative of HealthCap IV Bis | ||
| Christian Chavy, Director | ||
| Pr MBA, Independent Director | ||
| Emmanuel Fougeroux, Director of Accounting | ||
| Sir CPA, GM CEO | ||
| Olivier Martinez, Director | ||
| Shawn Benoit, Management Controller | ||
| JeanLouis Dasseux, Director |
Abionyx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abionyx Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.92 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (1.78) % | |||
| Operating Margin | (1.78) % | |||
| Current Valuation | 51.58 M | |||
| Shares Outstanding | 28.09 M | |||
| Shares Owned By Insiders | 32.46 % | |||
| Shares Owned By Institutions | 11.99 % | |||
| Price To Earning | 17.78 X | |||
| Price To Book | 5.91 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Abionyx Stock
Abionyx Pharma financial ratios help investors to determine whether Abionyx Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Abionyx with respect to the benefits of owning Abionyx Pharma security.